CeriBell (NASDAQ:CBLL) Research Coverage Started at William Blair

William Blair began coverage on shares of CeriBell (NASDAQ:CBLL) in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the stock. William Blair also issued estimates for CeriBell’s Q3 2024 earnings at ($0.25) EPS, Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.02) EPS and FY2026 earnings at ($0.91) EPS.

CeriBell Price Performance

Shares of NASDAQ CBLL opened at $28.95 on Tuesday. CeriBell has a fifty-two week low of $23.00 and a fifty-two week high of $29.53.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.